| Similar Articles |
|---|
 |
The Motley Fool
December 22, 2011
Rick Aristotle Munarriz |
Recalls Dampen Holiday Cheer Wal-Mart and Target have holiday recalls on their hands.   |
The Motley Fool
February 11, 2009
Rick Aristotle Munarriz |
This IPO Is Hot, Baby Baby formula maker Mead Johnson goes public, snatched from the womb of parent Bristol-Myers Squibb and displayed to the cheering masses. |
The Motley Fool
November 17, 2009
Brian Orelli |
Up 80%, It's Time to Sell Bristol-Myers to Mead Johnson: It's time to walk on your own. Investors will have an option of exchanging some or all of their Bristol-Myers shares for shares in Mead Johnson for a slight discount |
The Motley Fool
September 17, 2008
Brian Orelli |
IPO? In This Market? Bristol-Myers continues with plans to spin off its nutritionals business. |
The Motley Fool
January 17, 2012
Brian Orelli |
Pharma Focus Is Good For Your Portfolio Build your own portfolio. |
The Motley Fool
June 7, 2006
Brian Gorman |
Martek's Formula for Success Dependence on one customer could spell trouble for this nutritional supplement maker. Investors, take note. |
The Motley Fool
December 29, 2011
Dan Caplinger |
Why the Dow's Moving Higher Today As of midafternoon, all 30 Dow components were higher, with financials again leading the way. |
The Motley Fool
January 4, 2010
Rick Aristotle Munarriz |
5 Biggest IPO Winners of 2009 Last year's hottest rookies are unlikely heroes. |
The Motley Fool
September 23, 2010
Brian Orelli |
This Recall Should Bug You Abbott Labs announces a recall of some types of its Similac baby formula because it found beetles and their larvae in an area of one of its plants. |
The Motley Fool
February 19, 2009
Robert Steyer |
IPO Food for Thought The bosses at Pfizer should be interested in the recent Mead Johnson IPO so as to place a value on Wyeth's nutrition business. |
The Motley Fool
August 29, 2011
Brian Orelli |
A Less Painful FDA Decision Johnson & Johnson gains approval of Nucynta ER. |
The Motley Fool
February 28, 2011
Brian Orelli |
Johnson & Johnson Parties Like It's 1982 The big pharma announced that it was recalling 667,632 packages of Sudafed tablets because the instructions contained a typo. |
The Motley Fool
December 14, 2009
Rick Aristotle Munarriz |
Rumble in the S&P 500 Jungle By the end of the trading week, Visa and Mead Johnson Nutrition will be added to the S&P 500, where they will take the place of Ciena and MBIA |
The Motley Fool
October 21, 2010
Brian Orelli |
Abbott Just Can't Get Any Love Despite meeting or beating analysts' earnings for a streak that stretches balk half a decade, Abbott Labs hasn't been able to get much love from investors. |
The Motley Fool
February 13, 2009
Rick Aristotle Munarriz |
This Week's 5 Smartest Stock Moves Take a look at five smart business moves from last week: Successful IPO for Mead Johnson... Netflix passes the 10 million subscriber mark... Retail sales rose... Live Nation and Ticketmaster join forces... Guitar Hero publisher Activision rocks... |
The Motley Fool
May 28, 2010
Brian Orelli |
How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem? |
The Motley Fool
May 26, 2010
Brian Orelli |
Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues. |
The Motley Fool
August 24, 2009
Brian Orelli |
J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell. |
The Motley Fool
July 8, 2011
Brian Orelli |
Half a Breakup Is Better Than No Breakup at All Pfizer keeps two divisions and puts two on the chopping block. |
The Motley Fool
September 2, 2010
Seth Jayson |
Are Shorts Watching Mead Johnson Nutrition Co.? Will Mead Johnson Nutrition miss its numbers in the next quarter or two? Look here for a clue. |
The Motley Fool
June 28, 2011
Eric Bleeker |
Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales? |
The Motley Fool
July 14, 2008
Brian Orelli |
Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut? |
The Motley Fool
March 20, 2009
Brian Orelli |
No More Tears, Far More Fears? China's Food and Drug Administration said that it's investigating products made by our beloved Johnson & Johnson, after a U.S. group reported that there may be carcinogens in J&J's baby shampoo. |
U.S. CPSC
January 22, 2007 |
Next Step Plastic Sippy/Tumbler Cups Recalled for Laceration Hazard The impact of being dropped or banged can cause the cup to break into pieces, resulting in sharp or jagged edges that pose a laceration hazard to children. |
The Motley Fool
September 25, 2009
Brian Orelli |
Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK. |
The Motley Fool
July 31, 2007
Nathan Parmelee |
Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business. |
The Motley Fool
November 21, 2008
Brian Orelli |
Manufacturing Pain Johnson & Johnson has plenty of it. |
The Motley Fool
January 18, 2012 |
What Johnson & Johnson Does With Its Cash Over the last five years, Johnson & Johnson shares returned 14%, which drops to -3% without dividends -- not a bad boost to top off otherwise lowly share performance. |
The Motley Fool
July 9, 2010
Brian Orelli |
Hey, Johnson & Johnson: Eight Is Enough If Johnson & Johnson can't overcome the negative image from recalls quickly, consumers will head to competing brand-name drugs or just grab generic versions of Johnson & Johnson's products. |
The Motley Fool
May 12, 2010
Nick Kapur |
J&J: A Winner on Both Sides of the Ball (Fool TV) If you're looking to build a dynasty in your portfolio, you'd be hard-pressed to find a better-balanced outfit than veteran Johnson & Johnson. The consumer products giant is discussed in this video. |
The Motley Fool
February 17, 2011
Alex Dumortier |
Seize Your Chance to Beat the Pros! An area of genuine opportunity for the small investor. Spinoffs remain an underappreciated area in which the individual investor actually gains an edge over institutions. |
The Motley Fool
February 22, 2010
Alex Dumortier |
7 Stocks Hedge Funds Like Hedge funds were battered by losses and investor redemptions during the worst of the financial crisis, but now that the industry has regained some of its swagger, it might be worth asking: Which stocks has the "smart money" been buying? |
The Motley Fool
January 26, 2010
Brian Orelli |
Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years. |
The Motley Fool
September 30, 2009
Brian Orelli |
Boston Scientific Pays Up And Johnson & Johnson reaps the rewards. |
The Motley Fool
March 22, 2010
Rick Aristotle Munarriz |
4 Dividend Stocks Showing You the Money Mead Johnson Nutrition... Garmin... Prospect Capital... Guess?... |
The Motley Fool
August 14, 2007
Brian Orelli |
A No-Win Situation Johnson & Johnson is suing the beloved American Red Cross for trademark infringement. Johnson & Johnson just needs to walk a fine line between having its brand eroded by the Red Cross and having its brand eroded by a public relations nightmare. |
The Motley Fool
December 31, 2009
Brian Orelli |
The FDA (Still) Hates Antibiotic Makers Johnson & Johnson and Basilea are the agency's latest victims. |
The Motley Fool
November 26, 2010
Brian Orelli |
Get It Together, Johnson & Johnson Another day, another recall. |
The Motley Fool
July 20, 2010
Brian Orelli |
Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant. |
The Motley Fool
July 19, 2011
Brian Orelli |
J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile. |
The Motley Fool
April 29, 2011
David Williamson |
Johnson & Johnson's Traumatic Purchase Johnson & Johnson agrees to purchase trauma and spine specialist Synthes. |
The Motley Fool
July 12, 2011
Todd Wenning |
What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors. |
The Motley Fool
July 18, 2006
Stephen D. Simpson |
Can J&J Do Better Than GDP? Investors and analysts are obsessed with growth, but Johnson & Johnson isn't. |
The Motley Fool
June 15, 2011
Brian Orelli |
Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market. |
The Motley Fool
January 29, 2010
Brian Orelli |
All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time. |
The Motley Fool
October 12, 2004
Alyce Lomax |
Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson? |
The Motley Fool
August 24, 2010
Brian Orelli |
One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well. |
The Motley Fool
October 11, 2007
Rich Smith |
Quick Take: Johnson & Johnson Jilts Junior In response to an FDA warning of rare instances of abuse, Johnson & Johnson, Wyeth and Novartis all stop selling their infant cough syrups. |
The Motley Fool
June 4, 2010
Brian Orelli |
Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other. |
The Motley Fool
August 27, 2010
Brian Orelli |
A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much. |
